Ownership Change to Note: PDL Biopharma Inc (NASDAQ:PDLI) 2016 Q2 Institutional Investor Sentiment Steady

December 1, 2016 - By Marguerite Chambers   ·   0 Comments

Ownership Change to Note: PDL Biopharma Inc (NASDAQ:PDLI)  2016 Q2 Institutional Investor Sentiment Steady

Sentiment for PDL Biopharma Inc (NASDAQ:PDLI)

PDL Biopharma Inc (NASDAQ:PDLI) institutional sentiment decreased to 1 in 2016 Q2. Its down -0.23, from 1.23 in 2016Q1. The ratio turned negative, as 87 active investment managers started new or increased equity positions, while 71 cut down and sold stock positions in PDL Biopharma Inc. The active investment managers in our partner’s database reported: 118.91 million shares, down from 123.91 million shares in 2016Q1. Also, the number of active investment managers holding PDL Biopharma Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 20 Reduced: 51 Increased: 64 New Position: 23.

PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The company has a market cap of $351.45 million. The Firm provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It has a 2.09 P/E ratio. It evaluates its investments based on the quality of the income generating assets and potential returns on investment.

About 685,650 shares traded hands. PDL BioPharma Inc (NASDAQ:PDLI) has declined 41.76% since April 28, 2016 and is downtrending. It has underperformed by 47.68% the S&P500.

Analysts await PDL BioPharma Inc (NASDAQ:PDLI) to report earnings on February, 27. They expect $0.16 EPS, down 73.77% or $0.45 from last year’s $0.61 per share. PDLI’s profit will be $25.33 million for 3.47 P/E if the $0.16 EPS becomes a reality. After $0.11 actual EPS reported by PDL BioPharma Inc for the previous quarter, Wall Street now forecasts 45.45% EPS growth.

According to Zacks Investment Research, “Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.”

Tfs Capital Llc holds 0.34% of its portfolio in PDL BioPharma Inc for 592,849 shares. Gsa Capital Partners Llp owns 1.32 million shares or 0.23% of their US portfolio. Moreover, Ativo Capital Management Llc has 0.21% invested in the company for 274,065 shares. The California-based Rbf Capital Llc has invested 0.17% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 6.24 million shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 1 insider purchase, and 0 sales for $29,950 net activity.

PDL BioPharma Inc (NASDAQ:PDLI) Ratings Coverage

Ratings analysis reveals 0 of PDL BioPharma’s analysts are positive. Out of 2 Wall Street analysts rating PDL BioPharma, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $4 while the high is $7. The stock’s average target of $4 is 80.18% above today’s ($2.22) share price. PDLI was included in 5 notes of analysts from October 16, 2015. As per Tuesday, February 23, the company rating was maintained by RBC Capital Markets. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, November 5. The stock of PDL BioPharma Inc (NASDAQ:PDLI) earned “Sector Perform” rating by RBC Capital Markets on Friday, October 16. RBC Capital Markets maintained the shares of PDLI in a report on Tuesday, February 2 with “Sector Perform” rating.

PDLI Company Profile

PDL BioPharma, Inc., formerly Protein Design Labs, Inc., incorporated on July 24, 1986, manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Firm provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. The Firm evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others.

More notable recent PDL BioPharma Inc (NASDAQ:PDLI) news were published by: Fool.com which released: “Why PDL BioPharma Inc. Is Down 14.8% Today” on November 23, 2016, also Prnewswire.com with their article: “PDL BioPharma Issues $150.0 Million of 2.75% Convertible Senior Notes Due 2021” published on November 22, 2016, Prnewswire.com published: “PDL BioPharma to Present at the 28th Annual Piper Jaffray Healthcare Conference” on November 22, 2016. More interesting news about PDL BioPharma Inc (NASDAQ:PDLI) were released by: Prnewswire.com and their article: “PDL BioPharma Prices Public Offering of $150.0 Million of 2.75% Convertible …” published on November 17, 2016 as well as Fool.com‘s news article titled: “Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL …” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>